SA PRO
Free Account
Theravance Biopharma, Inc.TBPHNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
14 analysts·Moderate coverage
43%
Rating Distribution
Strong Buy
00%
Buy
643%
Hold
536%
Sell
321%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 69% higher.

Bear Case
$27.00
+36%
Consensus
$33.50
+69%
Bull Case
$40.00
+102%
Price Range14 analysts
Low
Consensus
High
$27.00
$40.00
Current Target
Current Price
$19.83
Upside to Target
$13.67

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 3, 2025Oppenheimer
Theravance Biopharma initiated with an Outperform at Oppenheimer
Target:$27.00
+46.5%from $18.43
Nov 26, 2025BTIG
Theravance Biopharma price target raised to $40 from $25 at BTIG
Target:$40.00
+111.2%from $18.94
Nov 13, 2024Leerink Partners
Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH)
Target:$10.00
+30.5%from $7.66
Aug 6, 2024H.C. Wainwright
Theravance Biopharma price target lowered to $15 from $20 at H.C. Wainwright
Target:$15.00
+56.4%from $9.59
Apr 12, 2024BTIG
BTIG Starts Theravance Biopharma (TBPH) at Buy
Target:$21.00
+135.2%from $8.93
Nov 17, 2022Leerink Partners
SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14
Target:$14.00
+24.8%from $11.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance